National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 1122743

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 3/26/2021

VAERS ID: 1122743
VAERS Form:2
Age:46.0
Sex:Female
Location:Massachusetts
Vaccinated:2021-02-05
Onset:2021-02-19
Submitted:0000-00-00
Entered:2021-03-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / 1 - / OT

Administered by: Private      Purchased by: ??
Symptoms: Blood culture, Blood pressure decreased, C-reactive protein, Cardiogenic shock, Cough, Myalgia, Myocarditis, Pyrexia, Respiratory failure, Serum ferritin, Thrombocytopenia, Thrombosis, Peripheral swelling, Ejection fraction, Haemorrhage, Investigation, Interleukin-2 receptor assay, Blood pressure measurement, SARS-CoV-2 test

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? Yes
Hospitalized? Yes, days: 20     Extended hospital stay? No
Previous Vaccinations:
Other Medications: ATORVASTATIN; ASPIRIN [ACETYLSALICYLIC ACID]; VITAMIN D [COLECALCIFEROL]
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: COVID-19 pneumonia (the patient was diagnosed with COVID-19 pneumonia prior to the vaccination); Hyperlipidemia
Allergies:
Diagnostic Lab Data: Test Date: 20210225; Test Name: Blood cultures; Result Unstructured Data: Test Result:no growth; Test Date: 20210224; Test Name: Blood pressure; Result Unstructured Data: Test Result:hypotensive despite pressors; Test Date: 20210226; Test Name: CRP; Result Unstructured Data: Test Result:$g 300; Test Date: 20210224; Test Name: LVEF; Test Result: 35 %; Test Date: 20210226; Test Name: Soluble IL2 receptor; Result Unstructured Data: Test Result:7232 pg/mL; Comments: elevated at 7232 pg/mL; Test Date: 20210226; Test Name: HLH; Result Unstructured Data: Test Result:Evaluated; Test Date: 20210224; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210225; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210311; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210314; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210226; Test Name: ferritin; Result Unstructured Data: Test Result:3054
CDC 'Split Type': USPFIZER INC2021295836

Write-up: severe thrombocytopenia; Bleeding at Impella insertion site; peripheral swelling in hands/feet; cardiogenic shock; myocarditis; hypoxic respiratory failure; mural thrombus; hypotensive despite pressors; fever; cough; myalgias; This is a spontaneous report from a contactable physician. A 46-year-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number and Expiration date was not provided), intramuscularly on 05Feb2021 as a single dose for COVID-19 immunisation. The patient''s medical history included hyperlipidemia and COVID-19 pneumonia from an unspecified date in Jan2021 to an unspecified date in Jan2021 (the patient was diagnosed with COVID-19 pneumonia prior to the vaccination. Recovered. Returned to work on 25Jan2021). Concomitant medications included atorvastatin orally at 10 mg, once a day, acetylsalicylic acid (ASPIRIN) orally at 81 mg, once a day, colecalciferol (VITAMIN D); all the drugs were received within two weeks. The patient previously took clindamycin and experienced known allergies: Clindamycin. The patient did not receive other vaccine in four weeks. The patient developed fever, cough, myalgias on 19Feb2021 at 12:00 AM. She developed peripheral swelling in hands/feet on 24Feb2021, she was evaluated in the ER; admitted to (hospital name withheld) on 24Feb2021 with cardiogenic shock, myocarditis, hypoxic respiratory failure. The patient was started on IV vancomycin and Unasyn. TTE (transthoracic echocardiogram) demonstrated LVEF (left ventricular ejection fraction) 35%; reduced biventricular function; mural thrombus on 24Feb2021. Remained hypotensive despite pressors on 24Feb2021. Patient had elevated PCW with preserved cardiac index. Patient underwent VA ECMO (veno-arterial extracorporeal membrane oxygenation) and Impella placement on 25Feb2021. COVID-19 PCR was negative. Blood cultures were no growth. She developed severe thrombocytopenia and developed bleeding at Impella insertion site on 25Feb2021; required multiple, PRBC transfusions. Evaluated for HLH; Soluble IL2 receptor on 26Feb2021 elevated at 7232 pg/mL; ferritin 3054; CRP $g 300. ECMO stopped 03Mar2021. The patient was treated with IV antibiotics, mechanical ventilation, pressor support, underwent VA ECMO and Impella placement. The patient was hospitalized from 24Feb2021 to 16Mar2021. Number of days of hospitalization was 20 days. The patient tested COVID post vaccination. The patient underwent lab tests and procedures which included blood pressure: hypotensive despite pressors, LVEF: 35 %, nasal swab: Negative on 24Feb2021, blood cultures: No growth, nasal swab: Negative on 25Feb2021, ferritin: 3054, HLH: Evaluated, Soluble IL2 receptor: 7232 pg/mL (elevated at 7232 pg/mL), CRP: $g 300 on 26Feb2021, nasal swab: Negative on 11Mar2021, nasal swab: Negative on 14Mar2021. The events were considered as serious (hospitalization and life threatening) by the physician. The outcome of the events was recovering. Information about lot/batch number has been requested.; Sender''s Comments: the events being serious, life threatening and hospitalisation ,medical intervention required are assessed as possibly related to the suspect drug __BNT162B2____ based on strong temporal association, but consider also possible contributory effects from patient''s medical history and/or concomitant medications.


Changed on 5/7/2021

VAERS ID: 1122743 Before After
VAERS Form:2
Age:46.0
Sex:Female
Location:Massachusetts
Vaccinated:2021-02-05
Onset:2021-02-19
Submitted:0000-00-00
Entered:2021-03-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / 1 - / OT

Administered by: Private      Purchased by: ??
Symptoms: Blood culture, Blood pressure decreased, C-reactive protein, Cardiogenic shock, Cough, Myalgia, Myocarditis, Pyrexia, Respiratory failure, Serum ferritin, Thrombocytopenia, Thrombosis, Peripheral swelling, Ejection fraction, Haemorrhage, Investigation, Interleukin-2 receptor assay, Blood pressure measurement, SARS-CoV-2 test

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? Yes
Hospitalized? Yes, days: 20     Extended hospital stay? No
Previous Vaccinations:
Other Medications: ATORVASTATIN; ASPIRIN [ACETYLSALICYLIC ACID]; VITAMIN D [COLECALCIFEROL]
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: COVID-19 pneumonia (the patient was diagnosed with COVID-19 pneumonia prior to the vaccination); Hyperlipidemia
Allergies:
Diagnostic Lab Data: Test Date: 20210225; Test Name: Blood cultures; Result Unstructured Data: Test Result:no growth; Test Date: 20210224; Test Name: Blood pressure; Result Unstructured Data: Test Result:hypotensive despite pressors; Test Date: 20210226; Test Name: CRP; Result Unstructured Data: Test Result:$g 300; Test Date: 20210224; Test Name: LVEF; Test Result: 35 %; Test Date: 20210226; Test Name: Soluble IL2 receptor; Result Unstructured Data: Test Result:7232 pg/mL; Comments: elevated at 7232 pg/mL; Test Date: 20210226; Test Name: HLH; Result Unstructured Data: Test Result:Evaluated; Test Date: 20210224; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210225; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210311; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210314; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210226; Test Name: ferritin; Result Unstructured Data: Test Result:3054
CDC 'Split Type': USPFIZER INC2021295836

Write-up: severe thrombocytopenia; Bleeding at Impella insertion site; peripheral swelling in hands/feet; cardiogenic shock; myocarditis; hypoxic respiratory failure; mural thrombus; hypotensive despite pressors; fever; cough; myalgias; This is a spontaneous report from a contactable physician. A 46-year-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number and Expiration date was not provided), intramuscularly on 05Feb2021 as a single dose for COVID-19 immunisation. The patient''s medical history included hyperlipidemia and COVID-19 pneumonia from an unspecified date in Jan2021 to an unspecified date in Jan2021 (the patient was diagnosed with COVID-19 pneumonia prior to the vaccination. Recovered. Returned to work on 25Jan2021). Concomitant medications included atorvastatin orally at 10 mg, once a day, acetylsalicylic acid (ASPIRIN) orally at 81 mg, once a day, colecalciferol (VITAMIN D); all the drugs were received within two weeks. The patient previously took clindamycin and experienced known allergies: Clindamycin. The patient did not receive other vaccine in four weeks. The patient developed fever, cough, myalgias on 19Feb2021 at 12:00 AM. She developed peripheral swelling in hands/feet on 24Feb2021, she was evaluated in the ER; admitted to (hospital name withheld) on 24Feb2021 with cardiogenic shock, myocarditis, hypoxic respiratory failure. The patient was started on IV vancomycin and Unasyn. TTE (transthoracic echocardiogram) demonstrated LVEF (left ventricular ejection fraction) 35%; reduced biventricular function; mural thrombus on 24Feb2021. Remained hypotensive despite pressors on 24Feb2021. Patient had elevated PCW with preserved cardiac index. Patient underwent VA ECMO (veno-arterial extracorporeal membrane oxygenation) and Impella placement on 25Feb2021. COVID-19 PCR was negative. Blood cultures were no growth. She developed severe thrombocytopenia and developed bleeding at Impella insertion site on 25Feb2021; required multiple, PRBC transfusions. Evaluated for HLH; Soluble IL2 receptor on 26Feb2021 elevated at 7232 pg/mL; ferritin 3054; CRP $g 300. ECMO stopped 03Mar2021. The patient was treated with IV antibiotics, mechanical ventilation, pressor support, underwent VA ECMO and Impella placement. The patient was hospitalized from 24Feb2021 to 16Mar2021. Number of days of hospitalization was 20 days. The patient tested COVID post vaccination. The patient underwent lab tests and procedures which included blood pressure: hypotensive despite pressors, LVEF: 35 %, nasal swab: Negative on 24Feb2021, blood cultures: No growth, nasal swab: Negative on 25Feb2021, ferritin: 3054, HLH: Evaluated, Soluble IL2 receptor: 7232 pg/mL (elevated at 7232 pg/mL), CRP: $g 300 on 26Feb2021, nasal swab: Negative on 11Mar2021, nasal swab: Negative on 14Mar2021. The events were considered as serious (hospitalization and life threatening) by the physician. The outcome of the events was recovering. Information about lot/batch number has been requested.; Sender''s Comments: the events being serious, life threatening and hospitalisation ,medical intervention required are assessed as possibly related to the suspect drug __BNT162B2____ based on strong temporal association, but consider also possible contributory effects from patient''s medical history and/or concomitant medications.


Changed on 5/14/2021

VAERS ID: 1122743 Before After
VAERS Form:2
Age:46.0
Sex:Female
Location:Massachusetts
Vaccinated:2021-02-05
Onset:2021-02-19
Submitted:0000-00-00
Entered:2021-03-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / 1 - / OT

Administered by: Private      Purchased by: ??
Symptoms: Blood culture, Blood pressure decreased, C-reactive protein, Cardiogenic shock, Cough, Myalgia, Myocarditis, Pyrexia, Respiratory failure, Serum ferritin, Thrombocytopenia, Thrombosis, Peripheral swelling, Ejection fraction, Haemorrhage, Investigation, Interleukin-2 receptor assay, Blood pressure measurement, SARS-CoV-2 test

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? Yes
Hospitalized? Yes, days: 20     Extended hospital stay? No
Previous Vaccinations:
Other Medications: ATORVASTATIN; ASPIRIN [ACETYLSALICYLIC ACID]; VITAMIN D [COLECALCIFEROL]
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: COVID-19 pneumonia (the patient was diagnosed with COVID-19 pneumonia prior to the vaccination); Hyperlipidemia
Allergies:
Diagnostic Lab Data: Test Date: 20210225; Test Name: Blood cultures; Result Unstructured Data: Test Result:no growth; Test Date: 20210224; Test Name: Blood pressure; Result Unstructured Data: Test Result:hypotensive despite pressors; Test Date: 20210226; Test Name: CRP; Result Unstructured Data: Test Result:$g 300; Test Date: 20210224; Test Name: LVEF; Test Result: 35 %; Test Date: 20210226; Test Name: Soluble IL2 receptor; Result Unstructured Data: Test Result:7232 pg/mL; Comments: elevated at 7232 pg/mL; Test Date: 20210226; Test Name: HLH; Result Unstructured Data: Test Result:Evaluated; Test Date: 20210224; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210225; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210311; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210314; Test Name: Nasal Swab; Test Result: Negative ; Test Date: 20210226; Test Name: ferritin; Result Unstructured Data: Test Result:3054
CDC 'Split Type': USPFIZER INC2021295836

Write-up: severe thrombocytopenia; Bleeding at Impella insertion site; peripheral swelling in hands/feet; cardiogenic shock; myocarditis; hypoxic respiratory failure; mural thrombus; hypotensive despite pressors; fever; cough; myalgias; This is a spontaneous report from a contactable physician. A 46-year-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number and Expiration date was not provided), intramuscularly on 05Feb2021 as a single dose for COVID-19 immunisation. The patient''s medical history included hyperlipidemia and COVID-19 pneumonia from an unspecified date in Jan2021 to an unspecified date in Jan2021 (the patient was diagnosed with COVID-19 pneumonia prior to the vaccination. Recovered. Returned to work on 25Jan2021). Concomitant medications included atorvastatin orally at 10 mg, once a day, acetylsalicylic acid (ASPIRIN) orally at 81 mg, once a day, colecalciferol (VITAMIN D); all the drugs were received within two weeks. The patient previously took clindamycin and experienced known allergies: Clindamycin. The patient did not receive other vaccine in four weeks. The patient developed fever, cough, myalgias on 19Feb2021 at 12:00 AM. She developed peripheral swelling in hands/feet on 24Feb2021, she was evaluated in the ER; admitted to (hospital name withheld) on 24Feb2021 with cardiogenic shock, myocarditis, hypoxic respiratory failure. The patient was started on IV vancomycin and Unasyn. TTE (transthoracic echocardiogram) demonstrated LVEF (left ventricular ejection fraction) 35%; reduced biventricular function; mural thrombus on 24Feb2021. Remained hypotensive despite pressors on 24Feb2021. Patient had elevated PCW with preserved cardiac index. Patient underwent VA ECMO (veno-arterial extracorporeal membrane oxygenation) and Impella placement on 25Feb2021. COVID-19 PCR was negative. Blood cultures were no growth. She developed severe thrombocytopenia and developed bleeding at Impella insertion site on 25Feb2021; required multiple, PRBC transfusions. Evaluated for HLH; Soluble IL2 receptor on 26Feb2021 elevated at 7232 pg/mL; ferritin 3054; CRP $g 300. ECMO stopped 03Mar2021. The patient was treated with IV antibiotics, mechanical ventilation, pressor support, underwent VA ECMO and Impella placement. The patient was hospitalized from 24Feb2021 to 16Mar2021. Number of days of hospitalization was 20 days. The patient tested COVID post vaccination. The patient underwent lab tests and procedures which included blood pressure: hypotensive despite pressors, LVEF: 35 %, nasal swab: Negative on 24Feb2021, blood cultures: No growth, nasal swab: Negative on 25Feb2021, ferritin: 3054, HLH: Evaluated, Soluble IL2 receptor: 7232 pg/mL (elevated at 7232 pg/mL), CRP: $g 300 on 26Feb2021, nasal swab: Negative on 11Mar2021, nasal swab: Negative on 14Mar2021. The events were considered as serious (hospitalization and life threatening) by the physician. The outcome of the events was recovering. Information about lot/batch number has been requested.; Sender''s Comments: the events being serious, life threatening and hospitalisation ,medical intervention required are assessed as possibly related to the suspect drug __BNT162B2____ based on strong temporal association, but consider also possible contributory effects from patient''s medical history and/or concomitant medications.


Record is removed as of 11/12/2021

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1122743&WAYBACKHISTORY=ON


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166